Our Team

Todd Harrison

Todd Harrison is the Founding Partner / Chief Investment Officer of CB1 Capital Management. Todd has spent over 35 years on Wall Street managing risk and researching financial market strategies. His institutional experience includes Morgan Stanley Equity Derivatives (VP), The Galleon Group (MD), and Cramer, Berkowitz LLC (President / Head of Trading).

Todd was also the Founder and CEO of Minyanville Media, Inc., an Emmy Award winning financial media company that covered global markets in real-time, developed, and licensed investment content to broker-dealers, and wrote real-time content that enabled millions of traders and investors to make more informed financial decisions. He oversaw all operating segments, enterprise relationships, dot-com properties, investment products and newsletters, gaming platforms, production studios and events.

Todd is the co-founder of the Mission [Green] Alliance, an industry-wide collaboration that allows consumers of legal cannabis the option to round-up to the nearest dollar or otherwise donate to The Weldon Project and Mission [Green] allowing consumers to be the change they hope to see in advancing federal cannabis reform.

He was the founder & President of The Ruby Peck Foundation for Children’s Education; a member of the Young Presidents’ Organization (YPO) and he currently serves on the Advisory Board of the Nassau County Police Department Foundation. He has been active in the research of financial market learning tendencies among college students, and was a contributing author to “Threat, Intimidation, and Student Financial Market Knowledge: An Empirical Study,” published in the Journal of Education for Business. His first book, The Other Side of Wall Street, was published in 2011 by FT Press.

Todd won an Emmy Award in 2008 from The National Academy of Television Arts & Sciences for his role as Executive Producer of “Minyanville’s World in Review,” the first and only animated business news show. The Emmy was awarded for new approaches to business and financial reporting, recognizing the innovative way the show educated, entertained, and enlightened audiences about financial news.

Mr. Harrison has appeared on CNBC, FOX, FOX Business, MSNBC and Bloomberg television as a financial authority and has been quoted and covered in The New York Times, The Wall Street Journal, BusinessWeek, Worth, Fortune, Forbes, Barron’s, Dow Jones MarketWatch, New York Magazine and Canada’s National Post. He was featured in the 20th Anniversary documentary of Oliver Stone’s Wall Street and the 2013 documentary, Money for Nothing: Inside the Federal Reserve. Todd served the international spokesman for eSignal, a division of IDC, from 2012-2014.

He has a Bachelor of Science degree in Finance from Syracuse University and lives in Port Washington, New York.

Loren DeFalco

Loren DeFalco, CFP, is a Partner of CB1 and our Head of Research. Loren cured himself of epileptic seizures through a regime of CBD and cannabinoids nine years ago and continued to research ECS through medical journals and scientific developments. His intimate understanding of the ECS system and nutraceutical arena makes him an ideal choice to lead research efforts.

Prior to joining CB1, Loren was President of LAD Capital, Inc., a Vice President and financial representative at HSBC, and a Vice President of Financial Planning at MetLife Resources, after starting his career as a financial representative at Northwestern Mutual Financial Network. He has a Bachelor of Science in Business Administration degree from Long Island University.

I’ve spent the better part of my time since 2008 learning everything I could about the endocannabinoid system. I was driven to this material in search of a solution to my own health issues that I could not find a solution to, as the prescription medicine I was being prescribed was not working for my conditions.

Loren’s Story

In 2008, I had a massive seizure at the airport while waiting curbside for my ride home after a business trip. I woke up in an ambulance and had no idea where I was or where I had come from. It was quite scary. I went to a neurologist who ran tests on me. I was told that I had a “seizure disorder” and would need to take anti-seizure drugs or I would not be allowed to drive my car.

This was all very disturbing as I felt broken. The medication began to take its toll on me right away and the side effects were debilitating. The solution I was provided for the side effects of the medication was…MORE medication. I ended up taking five different prescription drugs that caused my body to break down even more to the point that I was no longer able to work.

I decided that it was time to take matters into my own hands and I started to research to find alternate ways of handling my new situation. This is when I came across the endocannabinoid system. My discovery was nothing short of revolutionary for my mind and body. I started to learn how diet and cannabinoids influenced disease in the body and completely changed my lifestyle. I started on a diet that was based on making sure I was balancing the omega 6 and omega 3 levels in my body as well as ingesting cannabinoids through hemp plant seeds and other sources.

Six months after I started my new lifestyle, focusing on the endocannabinoid system, I was cleared by my neurologist after my EEG showed no more seizure activity in my brain. Finally, I was able to shed all of my prescription drugs. Not only did my seizures stop, but I started to experience relief from other physical issues that I had been dealing with, such as sleeping issues and arthritic knee pain. This was amazing to me and I strived to learn more about this system that I had never heard of before and that had only been recently discovered.

Jon Tyras

Jon Tyras is a Partner of CB1 and our Chief Operating Officer, Chief Financial Officer and Chief Compliance Officer. Jon has spent over 20 years in the industry. He was most recently the Chief Financial Officer and General Counsel of the $15 billion public securities platform of Brookfield Asset Management, a leading global alternative asset manager with approximately $250 billion in AUM.

Before his 10+ years with Brookfield, Jon was a capital markets attorney with Paul Hastings LLP for eight years. Prior to his admission to the New York Bar, he spent four years with Ernst & Young, where he was a Certified Public Accountant. He has Bachelor of Science degrees in Finance and Accounting, cum laude, from Georgetown University and a Juris Doctor degree from the University of Pennsylvania Law School.

Josh Felker

Josh Felker is a Research Analyst at CB1, covering all medical & adult-use markets. Josh began covering the Canadian legalization initiative in November ’16 when the Canadian Task Force report signaled a real-world chance of legalization occurring. He has written extensively for FelkerInvesting.com before joining CB1 Capital. Josh is CSC accredited and has maintained a strict adherence to the Buffett/Munger/Klarrman-style of security analysis.

Andrew Pfeffer

Andrew is a Senior Trader at CB1 who works directly with the investment team. Andrew has been in equities for over 20 years. After spending some time on the buy side, Andrew spent 18 years in trading at Virtu Financial and its predecessor firms, a leading market maker and liquidity provider, and was Head of Trading for the Healthcare and Biotech sectors. He has a Bachelor of Arts degree from Cornell University.